Abstract: A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.

Abstract: A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.

Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.

Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.

Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.

Abstract: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.

Abstract: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.

Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.

Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.

Abstract: Use of protein CTHRC1 or its nucleic acid in preparation for reagents or kits for diagnosing cancer of liver, the method for diagnosing cancer of liver by using the nucleic acid of CTHRC1, kit comprising the antibody to CTHRC1 or nucleic acid probe specific for the CTHRC1 protein and label, and the method for detecting the specific expression of protein CTHRC1 are disclosed.

Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.

Abstract: The invention provides a method for diagnosing susceptibility of individual cancer (e.g. liver cancer), comprising the steps of detecting individual HC56 gene, transcript and/or protein, and comparing it with normal HC56 gene, transcript and/or protein. The difference show the possibility of individual cancer is higher than that in the normal population. The invention also provides the corresponding detection kit.

Abstract: The invention relates to a new kind of human protein associated with hepatoma and the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. The present invention also relates to a method of applying the polypeptide for the diagnosis and treatment of various kinds of disease, such as cancer. Further, present invention relates to the antagonist of the polypeptide and therapeutic use of the same. In addition, the invention relates to the use of the same. In addition, the invention relates to the use of polynucleotide encoding the hepatoma associated human protein.

Abstract: The invention related to a novel human tumor associated polypeptide CT120, and the encoding polynucleotide, and to the method for producing the polypeptide by recombinant technology, also to the method for diagnosing and treating diseases such as carcinoma using the polypeptide. The invention also related to antagonists against the polypeptide and its uses for treatment, aslo to the uses of the polynucleotide coding for the human tumor-associated protein.

Abstract: The present invention relates to a novel human longevity assurance protein, the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. The present invention also relates to a method of applying the polypeptide for the treatment of various kinds of disease, such as cancer. Further, the present invention relates to the antagonist of the polypeptide and therapeutic use of the same. In addition, the present invention includes the use of the polynucleotide encoding the human longevity assurance protein.

Abstract: The invention provides a method for diagnosing susceptibility of individual cancer (e.g. liver cancer), comprising the steps of detecting individual HC56 gene, transcript and/or protein, and comparing it with normal HC56 gene, transcript and/or protein. The difference show the possibility of individual cancer is higher than that in the normal population. The invention also provides the corresponding detection kit.

Abstract: The invention has disclosed a novel human longevity assurance protein, the polynucleotide encoding said polypeptide and a process for producing the polypeptide by recombinant methods. It has also disclosed the method of applying the polypeptide for the treatment of various kinds of disease, such as cancer. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, the invention has disclosed the use of polynucleotide encoding said human longevity assurance protein.

Abstract: The invention disclosed a new kind of human protein that associated with hepatoma and the polynucleotide encoding said polypeptide and a process for producing the polypeptide by recombinant methods. It also disclosed the method of applying the polypeptide for the diagnosis and treatment of various kinds of disease, such as cancer. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, the invention disclosed the use of the same. In addition, the invention refers to the use of polynucleotide encoding said hepatoma associated human protein.